{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:32:40Z","timestamp":1791689560064,"version":"4.3.4"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"\n Context:<\/jats:title>\n Osteogenesis imperfecta (OI) is a genetic disorder of the extracellular matrix of bone characterized by low bone mass manifesting as frequent fractures, delayed motor development, pain, and impaired quality of life. The intravenous bisphosphonate, pamidronate is an established treatment for OI. Recently, zoledronic acid (ZA) has been used for the management of OI.<\/jats:p>\n <\/jats:sec>\n \n Aim:<\/jats:title>\n To assess the efficacy and safety of ZA in children below five years of age with OI.<\/jats:p>\n <\/jats:sec>\n \n Settings and Design:<\/jats:title>\n A hospital-based prospective observational study.<\/jats:p>\n <\/jats:sec>\n \n Methods and Material:<\/jats:title>\n \n Patients with OI aged less than five years attending our centre were treated with intravenous ZA at a dose of 0.05 mg\/kg every six months. Subjects were closely monitored for clinical and biochemical variables, adverse events, and new-onset fractures. The response to therapy was assessed by monitoring clinical variables including the degree of bony pains, number of fractures, height\/length standard deviation score (SDS), and motor developmental milestones. All patients were analysed at baseline and at the end of two years for biochemical parameters and clinical severity score (CSS) as proposed by Aglan\n et al<\/jats:italic>\n . with modifications.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n After two years of treatment, OI patients showed a significant decline in the rate of fractures (\n p<\/jats:italic>\n < 0.001), improvement in ambulation (\n p<\/jats:italic>\n = 0.005), alleviation of pain (\n p<\/jats:italic>\n < 0.001), and improvement in height SDS (\n p<\/jats:italic>\n < 0.05). There was a significant improvement in CSS after two years of therapy. Apart from mild flu-like symptoms and mild asymptomatic hypocalcaemia immediately post-infusion, no other adverse effect was noted.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n ZA therapy in infants and children below five years of age with OI was effective and safe and a more convenient alternative to pamidronate.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijem.ijem_268_22","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T02:02:39Z","timestamp":1687744959000},"page":"255-259","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Zoledronic Acid Treatment in Infants and Toddlers with Osteogenesis Imperfecta is Safe and Effective: A Tertiary Care Centre Experience"],"prefix":"10.4103","volume":"27","author":[{"given":"Angad","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Gauhati Medical College and Hospital, Guwahati, Assam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma K.","family":"Saikia","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Gauhati Medical College and Hospital, Guwahati, Assam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok K.","family":"Bhuyan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Gauhati Medical College and Hospital, Guwahati, Assam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhamoni","family":"Baro","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Gauhati Medical College and Hospital, Guwahati, Assam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra G.","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Gauhati Medical College and Hospital, Guwahati, Assam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"540178","DOI":"10.4061\/2011\/540178","article-title":"Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta","volume":"2011","author":"Ben Amor","year":"2011","journal-title":"J Osteoporos"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"R3-20240828","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11832-012-0385-3","article-title":"A scoring system for the assessment of clinical severity in osteogenesis imperfecta","volume":"6","author":"Aglan","year":"2012","journal-title":"J Child Orthop"},{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000323368","article-title":"Zoledronic acid treatment in children with osteogenesis imperfecta","volume":"75","author":"Vuorimies","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1515\/jpem-2012-0016","article-title":"Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta","volume":"25","author":"Barros","year":"2012","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00198-015-3216-9","article-title":"Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome:A 2-year prospective observational study","volume":"27","author":"Otaify","year":"2016","journal-title":"Osteoporos Int"},{"key":"R7-20240828","first-page":"55","article-title":"Pain control:Pain assessment in infants and young children:The FLACC scale","volume":"102","author":"Merkel","year":"2002","journal-title":"Am J Nurs"},{"key":"R9-20240828","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ajhg.2012.06.005","article-title":"A single recurrent mutation in the 5\u2032-UTR of IFITM5 causes osteogenesis imperfecta type V","volume":"91","author":"Cho","year":"2012","journal-title":"Am J Hum Genet"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1359\/jbmr.2000.15.9.1650","article-title":"Type V osteogenesis imperfecta:A new form of brittle bone disease","volume":"15","author":"Glorieux","year":"2000","journal-title":"J Bone Miner Res"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ajhg.2011.01.015","article-title":"Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta","volume":"88","author":"Becker","year":"2011","journal-title":"Am J Hum Genet"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajhg.2010.05.016","article-title":"Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta","volume":"87","author":"Lapunzina","year":"2010","journal-title":"Am J Hum Genet"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/humu.21647","article-title":"Identification of a mutation causing deficient BMP1\/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta","volume":"33","author":"Mart\u00ednez-Glez","year":"2012","journal-title":"Hum Mutat"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","article-title":"Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta","volume":"16","author":"Devogelaer","year":"1987","journal-title":"Skeletal Radiol"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/01.bpb.0000192058.98484.5b","article-title":"Surgery versus surgery plus pamidronate in the management of osteogenesis imperfecta patients:A comparative study","volume":"15","author":"El Sobky","year":"2006","journal-title":"J Pediatr Orthop B"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1515\/JPEM.2009.22.1.55","article-title":"Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis","volume":"22","author":"Brown","year":"2009","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1651-2227.2007.00390.x","article-title":"Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta","volume":"96","author":"L\u00f6wing","year":"2007","journal-title":"Acta Paediatr"},{"key":"R19-20240828","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"R20-20240828","first-page":"77","article-title":"Modern approach to children with osteogenesis imperfecta","volume":"12","author":"Zeitlin","year":"2003","journal-title":"J Pediatr Orthop B"},{"key":"R21-20240828","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000323370","article-title":"Intravenous pamidronate treatment improves growth in prepubertal osteogenesis imperfecta patients","volume":"75","author":"Heino","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"R22-20240828","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pedneo.2013.12.001","article-title":"Cyclic pamidronate infusion for neonatal-onset osteogenesis imperfecta","volume":"55","author":"Lin","year":"2014","journal-title":"Pediatr Neonatol"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_268_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:13:42Z","timestamp":1787760822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_268_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_268_22","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"2022-07-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}